GliaPharm is a Swiss biotechnology company that develops treatments for neurological and psychiatric disorders.
GliaPharm's innovative therapeutic approach is to target glial cells, the 'support cells' of neurons, to sustain and enhance brain metabolism in pathological conditions. Our vision is to become a leading biotechnology company with a focus on glia-mediated pathways as agents for neuroprotection and maintenance of cognitive functions.
GliaPharm est une entreprise suisse de biotechnologies active dans le développement de traitements de maladies neurologiques et psychiatriques.
L'approche thérapeutique innovante de GliaPharm est de cibler les cellules gliales, ou 'cellules de soutien' des neurones, afin de soutenir et améliorer le métabolisme cérébral dans certaines conditions pathologiques. Notre vision est de devenir leader dans le développement d'agents ciblant les cellules gliales qui agissent comme neuroprotecteurs et maintiennent les fonctions cognitives.
SEPTEMBER 2020
GliaPharm to present at the European Congress of Neuropsychopharmacology - Symposium on "Beyond the Neurocentric Paradigm: Targeting Astrocytes and Neuroglial Interactions in CNS Disorders". September 13th 2020.
AUGUST 2020
GliaPharm to present at the virtual #FOXG1ScienceSymposium on August 17/18. Register here to tune in to hear from all the researchers, industry and more about the path to a cure for #FOXG1. #FOXG1SS2020
AUGUST 2020
GliaPharm presented at the LifeSci Partners Summer Symposium on August 5th 2020